Apr 252022

Halberd CEO Letter

April 25th, 2022|Categories: Featured, Investor News, News, Press Releases, Update Letter|Tags: , , , , |

Q1 Accomplishments and Q2 Plans Jackson Center, PA, April 25, 2022 Greetings From The CEO And Staff At HALBERD CORPORATION! (OTC: HALB) This past quarter has witnessed some very significant technical and organizational achievements by the Halberd team. Q1 OVERVIEW AND ACHIEVEMENTS Halberd demonstrated elimination of the final two of the “Top Ten” antigens linked to neurodegenerative diseases. Halberd demonstrated that its antigen elimination process is able to selectively eliminate target antigens from cerebral spinal ...

Apr 182022

Halberd Eliminates E. coli in 20 Minutes vs. 7-10 Days with Conventional Antibiotics

April 18th, 2022|Categories: Featured, Investor News, Medical, Press Releases|Tags: , , , , , , |

Jackson Center, PA, April 18, 2022 – Halberd Corporation (OTC PINK:HALB) demonstrated the efficacy of its patented extracorporeal methodology for treatment and eradication of disease states.  The latest success was again extracorporeal elimination of E. coli bacteria from cerebral spinal fluid (CSF) by exposure to tuned laser light, in vitro, in under 20 minutes.  This compares to up to 10 days using conventional antibiotic treatments as the current standard of care.  E. coli (Escherichia coli) ...

Apr 112022

Halberd Entering the Medical Metaverse(TM)

April 11th, 2022|Categories: Investor News, News, Press Releases|

Jackson Center, PA, April 11, 2022 – Halberd Corporation (OTC PINK:HALB) announces plans to enter the Metaverse by the creation of nonfungible tokens (NFT’s) to monetize certain intellectual properties of the company including but not limited to patents, patents pending, trade secrets, etc. Halberd is currently in negotiations to engage a team of experts in Metaverse with expertise in nonfungible tokens (NFT’s) who can identify growth opportunities by monitoring the evolving marketplace, setting category strategy, ...

Apr 42022

Halberd Continues In-Vitro Successes With Elimination of Protein Linked to Depression

April 4th, 2022|Categories: Investor News, Medical, News, Press Releases|

Jackson Center, PA, April 4, 2022 – Halberd Corporation (OTC PINK:HALB) demonstrated the extracorporeal elimination of C-Reactive Protein from cerebral spinal fluid (CSF) by exposure to tuned laser light, in vitro.  Halberd, encouraged by its recent success in eliminating all ten of the top antigens associated with PTSD (Post Traumatic Stress Disorder), CTE (Chronic Traumatic Encephalopathy) and numerous other neurodegenerative diseases, expanded their research to address elimination of the disease antigen associated with clinical depression ...

Mar 252022

Halberd Corporation Brief Overview

March 25th, 2022|Categories: Featured, News|

Halberd Corporation Brief Overview Halberd Corporation was re-formed in May 2020.  Noting that Halberd’s unique extracorporeal technological approach is adaptable to many disease states, Halberd’s team of professionals employed its skills, resources and focus to concentrate on developing treatments against some of the world’s more persistent diseases, such as, Alzheimer’s Disease, PTSD, Parkinson’s Disease, epilepsy and other neurodegenerative diseases, sepsis, meningitis, and pandemics, among others.  Except for select trade secrets, Halberd’s technology ...

Mar 162022

Infectious Disease Specialist Will Guide Halberd’s Extracorporeal Elimination of Disease Antigens in Animals and Then Humans

March 16th, 2022|Categories: Featured, Investor News, News, Press Releases|Tags: , |

Jackson Center, PA, March 16, 2022 – Halberd Corporation (OTC-PINK: "HALB") announces its entry into the next stage of research.  To guide it, having successfully eliminated the Top 10 Target Antigens associated with neurodegenerative diseases in vitro, Halberd is pleased to announce the addition of Ravi Venkata Durvasula, M.D., a renowned infectious disease specialist and educator, to its team of technical experts and consultants.  Dr. Durvasula will guide Halberd’s efforts in applying its patented extracorporeal ...

Go to Top